Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial

Gastroenterology

Volumn 117, Issue 4, 1999, Pages 918-925

  Leuschner, M ^a   Maier, K P ^a   Schlichting, J ^a   Strahl, S ^a   Herrmann, G ^a   Dahm, H H ^a   Ackermann, H ^a   Happ, J ^a   Leuschner, U ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; BONE DENSITY; BONE MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; FEMALE; FIRST PASS EFFECT; GLUCOSE TOLERANCE TEST; HUMAN; HYDROCORTISONE RELEASE; MALE; ORAL DRUG ADMINISTRATION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY;

EID: 0032873241     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(99)70351-3     Document Type: Article

References (32)

1. R David W Kurtz WD Strohm U Leuschner Die Wirkung von Ursodesoxycholsäure bei chronischen Leberkrankheiten. Eine Pilotstudie (abstr) Z Gastroenterol 23 1985 420
2. U Leuschner H Fischer W Kurtz S Güldütuna K Hübner A Hellstern M Gatzen M Leuschner Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double blind trial Gastroenterology 97 1989 1268 1274
3. RE Poupon R Poupon B Balkau UDC-PBC Study Group Ursodiol for the long-term treatment of primary biliary cirrhosis N Engl J Med 330 1994 1342 1347
4. B Combes RL Carithers WC Maddrey D Lin MF McDonald DE Wheeler EH Eigenbrodt SJ Muñoz R Rubin G Garcia-Tsao GF Bonner AB West JL Boyer VA Luketic ML Shiffman AS Mills MG Peters HM White RK Zetterman SS Rossi AF Hofmann RS Marking A randomized double blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis Hepatology 22 1995 759 766
5. EJ Heathcote K Cauch-Dudek V Walker R Bailey LM Blendis CN Ghent P Michieletti GY Minuk LJ Pappas Scully UP Steinbrecher LR Sutherland CN Williams H Witt-Sullivan LJ Worobetz RA Milnes IR Wanless The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis Hepatology 19 1994 1149 1156
6. U Leuschner S Güldütuna M Imhof K Hübner A Benjaminov M Leuschner Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis J Hepatol 21 1994 624 633
7. RE Poupon KD Lindor K Cauch-Dudek ER Dickson R Poupon EJ Heathcote Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis Gastroenterology 113 1997 884 890
8. LS Erikkson R Olsson H Glauman H Prytz R Befrits O Rydén K Einarsson S Lindgren S Wallerstedt M Wedén Ursodeoxycho-lic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study Scand J Gastroenterol 32 1997 179 186
9. KD Lindor ER Dickson WP Baldus RA Jorgensen J Ludwig PA Murtaugh JM Harrison RH Wiesner ML Anderson SM Lange G LeSage SS Rossi AF Hofmann Ursodeoxycholic acid in the treatment of primary biliary cirrhosis Gastroenterology 106 1994 1284 1290
10. M Leuschner S Güldütuna T You K Hübner S Bhatti U Leuschner Ursodeoxycholic acid and prednisolone versus ursodeoxycho-lic acid and placebo in the treatment of early stages of primary biliary cirrhosis J Hepatol 25 1996 49 57
11. HC Mitchison JM Palmer MF Bassendine AJ Watson CO Record OFW James A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results J Hepatol 15 1992 336 344
12. R Löfberg Å Danielsson L Salde Oral budesonide in ileocoecal Crohn's disease Aliment Pharmacol Ther 7 1993 611 616
13. GR Greenberg BG Feagan F Martin Oral budesonide for active Crohn's disease N Engl J Med 331 1994 836 841
14. HW Möllmann J Barth G Hochhaus AC Möllmann H Derendorf A Tromm Principles of topical versus systemic corticoid treatment in inflammatory bowel disease HW Möllmann B May Glucocorticoid therapy in chronic inflammatory bowel disease. From basic principles to rational therapy 1996 Kluwer Boston 42 60
15. Å Danielsson H Prytz Oral budesonide for treatment of autoimmune chronic active hepatitis Aliment Pharmacol Ther 8 1994 585 590
16. S Güldütuna T You W Kurts U Leuschner High-performance liquid chromatographic determination of free and conjugated bile acids in serum, liver biopsies, bile, gastric juice and feces by fluorescence labeling Clin Chim Acta 214 1993 195 207
17. J Ludwig ER Dickson GS McDonald Staging of chronic nonsup-purative destructive cholangitis (syndrome of primary biliary cirrhosis) Virchows Arch A 379 1978 103 112
18. S Sherlock J Dooley Diseases of the liver and biliary system 1993 Blackwell Scientific Cambridge, MA 39
19. R Brattsand Overview of newer glucocorticoid preparations for inflammatory bowel disease Can J Gastroenterol 4 1990 407 414
20. T Andus SR Targan Glucocorticoids SR Targan F Shanahan Inflammatory bowel disease: from bench to bedside 1994 Williams & Wilkins Baltimore, MD 487 502
21. H Bergstrand A Björnsson B Lindquist A Nilsson R Brattsand Inhibitory effect of glucocorticoids on anti-IgE–induced histamine release from human basophilic leucocytes: evidence for a dual mechanism of action Allergy 39 1984 217 230
22. H Bergstrand B Lindquist BA Petersson The glucocorticoste-roid, budesonide, partially blocks histamine release from human lung tissue in vitro Allergy 41 1986 319 326
23. RN Brogden D. McTavish Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis Drugs 44 1992 375 407
24. G Wür thwein S Rehder P Rohdewald Lipophilicity and receptor affinity of glucocorticoids Pharm Ztg Wiss 137 1992 161 167
25. Å Ryr feldt P Andersson S Edsbäcker M Tönnesson D Davies R Pauwels Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid Eur J Respir Dis 63 suppl122 1982 86 95
26. E Dahlberg A Thalén R Brattsand JA Gustafsson U Johansson K Roemke T Saartok Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16α,17α-acetal substituted glucocorticoids Mol Pharmacol 25 1983 70
27. L Sade A Lassus Systemic side-effects of three topical steroids in diseased skin Curr Med Res Opin 8 1983 475 480
28. G Jönsson A Åström P Andersson Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver Drug Metab Dispos 23 1995 137 142
29. S Edsbäcker P Andersson C Lindberg Å Ryr feldt A Thalén Metabolic acetal splitting of budesonide. A novel inactivation pathway for topical glucocorticoids Drug Metab Dispos 15 1987 412 417
30. FHJ Wolfhagen HJF van Hoogstraten HR van Buuren GP van Berge-Henegouwen FJW ten Kate WCJ Hop EW van der Hoek MJ Kerbert HH van Lijf JW den Ouden AM Smit RA de Vries RAA van Zanten SW Schalm Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study J Hepatol 29 1998 736 742
31. FHJ Wolfhagen HR van Buuren JW den Ouden WCJ Hop JPTM van Leeuwen SW Schalm HAP Pols Cyclic etidronate in the prevention of bone loss in corticoid-treated primary biliary cirrhosis A prospective, controlled pilot study J Hepatol 26 1997 325 330
32. HC Mitchison MF Bassendine AJ Malcolm AJ Watson CO Record OFN James A pilot, double-blind, controlled one year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss Hepatology 10 1989 420 429